AstraZeneca has doubled down on plans to grow its US business as it braces for the country’s potential tariffs on the pharmaceutical industry. The drug maker said it is "firmly committed to investing ...

It does not necessarily reflect the view of The Herald. AstraZeneca has doubled down on plans to grow its US business as it braces for the country’s potential tariffs on the pharmaceutical industry.

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) reported Tuesday that its first-quarter profit climbed from last year on sales growth. Further, the company reitereated its fiscal 2025 ...

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Our strong growth momentum has continued into 2025 and we have now entered an unprecedented catalyst-rich period for our company.

The United States is a key market for the pharmaceutical industry, and AstraZeneca had already planning to invest $3.5 billion there by the end of 2026. Soriot said earlier in the year that he ...

British pharmaceutical giant AstraZeneca announced Tuesday that it has begun moving some of its European production to the United States, ahead of President Donald Trump's possible tariffs on the ...

2 Months Online Access $1.98 for 60 days 3 Months Online Access $2.97 for 90 days 4 Months Online Access $3.96 for 120 days 5 Months Online Access $4.95 for 150 days 6 Months Online Access $5.94 for ...